Vandetanib

Vandetanib
Clinical data
Trade names	Caprelsa
Other names	ZD6474
AHFS/Drugs.com	Monograph
MedlinePlus	a611037
License data	US DailyMed: Vandetanib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EX04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	90–96%
Metabolism	CYP3A4, FMO1, FMO3
Elimination half-life	19 days (mean)
Excretion	44% faeces, 25% urine
Identifiers
	IUPAC name N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine;
CAS Number	443913-73-3 ;
PubChem CID	3081361;
IUPHAR/BPS	5717;
DrugBank	DB08764 ;
ChemSpider	2338979 ;
UNII	YO460OQ37K;
KEGG	D06407;
ChEBI	CHEBI:49960 ;
ChEMBL	ChEMBL24828 ;
PDB ligand	ZD6 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1046681 ;
ECHA InfoCard	100.195.611
Chemical and physical data
Formula	C22H24BrFN4O2
Molar mass	475.362 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br;
	InChI InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) ; Key:UHTHHESEBZOYNR-UHFFFAOYSA-N ;
	(what is this?) (verify)

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015.